X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

AI Customizes Synthesized DNA For Medication Development

Content Team by Content Team
28th November 2022
in Drug Development, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Researchers at Chalmers University of Technology in Sweden have created synthetic DNA that directs the cellular creation of proteins with the aid of an AI. With the help of technology, vaccines, medications for serious illnesses, and alternative dietary proteins might all be developed and produced considerably more quickly and inexpensively than they are now.

The mechanism by which the genes are translated is essential to the operation of cells in all living beings. Simply put, the messenger RNA (mRNA) molecule receives instructions from the genetic code in DNA about which proteins to generate and in what quantities.

Controlling gene expression is a major area of research since it can, among other things, aid in the creation of protein-based medicines. A current illustration is the COVID-19 mRNA vaccine, which sent instructions to the body’s cells to generate the same protein found on the coronavirus’s surface. The immune system of the body could potentially develop antibodies against the pathogen. Likewise, by comprehending the genetic code that controls the creation of particular proteins, it is feasible to instruct the body’s immune system to eradicate cancer cells or other complex disorders.

The majority of today’s new medications are protein-based, but because it is challenging to regulate how the DNA is produced, the methods used to make them are both time-consuming and costly. Associate Professor of Systems Biology at Chalmers University, Aleksej Zelezniak, and his team made significant progress last year toward knowing and controlling the amount of a protein produced from a specific DNA sequence.

The ability to completely read the DNA molecule’s contents came first. Now that they have been successful in creating their own DNA, which carries the precise instructions to regulate the amount of a certain protein, Aleksej Zelezniak outlines the most recent significant discovery made by the research team.

Custom DNA molecule production

The idea behind the new approach is comparable to how AI creates looks that resemble real people. The AI can then build entirely new but realistic-looking faces by studying the appearance of a wide range of faces. Then, it is simple to alter a face by telling it to look older or have a distinct hairdo, for example. Without the aid of AI, it would have been considerably more challenging and time-consuming to create a realistic face from scratch. The regulatory code and structure of DNA have also been taught to the researchers’ AI. The AI then creates synthetic DNA, where it is simple to alter its regulatory data to direct gene expression in the appropriate manner. Simply explained, the AI prints the correct DNA sequence after being instructed on how much of a gene is desired.

The molecule of DNA is extraordinarily lengthy and intricate. Thus, modifying it by repeatedly reading and changing it before rereading and altering it again presents a very difficult experimental problem. In this method, it takes years of study to discover a solution. It is considerably more efficient to let an AI discover the fundamentals of exploring DNA. Now, what would normally take years just takes weeks or days, as a research associate at Slovenia’s National Institute of Biology and a former postdoc in Aleksej Zelezniak’s group, first author Jan Zrimec, explains.

The yeast Saccharomyces cerevisiae, whose cells mimic those of mammals, is where the researchers created their technique. The utilisation of human cells is the next stage. The researchers are hoping that their work will influence the creation of both new and old medications.

The development of protein-based medicines for difficult diseases or alternative sustainable dietary proteins might take years and be very expensive. Some are economically unviable because they are so expensive that it is difficult to see a return on investment. With the aid of their technology, proteins may be developed and produced considerably more quickly so they can be sold, Aleksej Zelezniak adds.

Previous Post

Start of A Multi-Drug Trial For Precision Medicine Cancer

Next Post

Redesigning The Human Medicines Directive And Regulation

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Redesigning The Human Medicines Directive And Regulation

Redesigning The Human Medicines Directive And Regulation

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In